Search results
Results from the WOW.Com Content Network
Side effects of pseudoephedrine include insomnia, elevated heart rate, increased blood pressure, restlessness, dizziness, anxiety, and dry mouth, among others. [ 21 ] [ 2 ] [ 1 ] [ 22 ] Rarely, pseudoephedrine has been associated with serious cardiovascular complications like heart attack and hemorrhagic stroke .
Currently, the DSM-5 published in 2013 and the ICD-10 that came into effect in 1994 are used, with the latter in the process of being replaced by the ICD-11 that came into effect in 2022 and is now implemented by healthcare systems across the world. Which autism spectrum diagnoses can be made and which criteria are used depends on the local ...
A wide variety of alkaloid and non-alkaloid compounds have been identified in various species of ephedra.Of the six ephedrine-type ingredients found in ephedra (at concentrations of 0.02-3.4%), the most common are ephedrine and pseudoephedrine, [12] which are the sources of its stimulant and thermogenic effects. [3]
Ephedrine is a non-catecholamine sympathomimetic with cardiovascular effects similar to those of adrenaline/epinephrine: increased blood pressure, heart rate, and contractility. Like pseudoephedrine it is a bronchodilator, with pseudoephedrine having considerably less effect. [19] [20]
For example, a relatively small 2007 study of 5,484 eight-year-old children in Finland found 2.9 children per 1,000 met the ICD-10 criteria for an AS diagnosis, 2.7 per 1,000 for Gillberg and Gillberg criteria, 2.5 for DSM-IV, 1.6 for Szatmari et al., and 4.3 per 1,000 for the union of the four criteria.
The ICD-10 criteria for childhood autism postulate that abnormal or impaired development is evident before the age of 3 in receptive or expressive language used in social communication, development of selective social attachments or reciprocal social interactions, or functional and symbolic play.
A Clarinase Repetab tablet contains 5 mg loratadine in the tablet coating and 120 mg pseudoephedrine sulfate equally distributed between the tablet coating and the barrier-coated core. The two active components in the coating are quickly liberated; release of pseudoephedrine in the core is delayed for several hours.
Common side effects include sleepiness, constipation, and dry mouth. [10] Other side effects may include low blood pressure and urinary problems. [11] It appears to work by activating α 2A-adrenergic receptors in the brain, thereby decreasing sympathetic nervous system activity. [10] Guanfacine was first described by 1974 [12] and was approved ...